Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 4/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.51 |
| ▸ | DPP4 | P27487 | 8/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675245 | 0.86 | FAP (0.51) | FAPPREPDPP4PIK3CAPIK3CB | |
| SCHEMBL17282585 | 0.84 | FAP (0.48) | FAPPREPDPP4PIK3CAPIK3CB | |
| SCHEMBL18681161 | 0.76 | FAP (0.63) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL18681073 | 0.75 | PIK3CA (0.37) | FAPPREPDPP4PIK3CAPIK3CB | |
| SCHEMBL883054 | 0.70 | MEN1 (0.48) | FAPPREPPIK3CAPIK3CBPIK3CD | |
| SCHEMBL11770755 | 0.70 | PIK3CA (0.37) | PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL15756632 | 0.70 | PREP (0.34) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL18771284 | 0.70 | PIK3CA (0.36) | FAPPREPDPP4PIK3CAPIK3CB | |
| SCHEMBL5206653 | 0.69 | CHRM2 (0.41) | PREPPIK3CAPIK3CB | |
| SCHEMBL8244090 | 0.68 | FAP (1.00) | FAPPREPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | FAP 109/4885PREP 10/4885DPP4 75/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | FAP 206/4885PREP 16/4885DPP4 58/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | FAP 206/4885PREP 16/4885DPP4 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.